Total Payments
$9,113
2024 Payments
$78.31
Companies
32
Transactions
190
Medicare Patients
1,932
Medicare Billing
$400,030
Payment Breakdown by Category
Travel$5,003 (54.9%)
Food & Beverage$3,939 (43.2%)
Education$170.77 (1.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $5,003 | 8 | 54.9% |
| Food and Beverage | $3,939 | 177 | 43.2% |
| Education | $170.77 | 5 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $4,181 | 29 | $0 (2020) |
| Spectrum Pharmaceuticals Inc. | $1,793 | 7 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $996.04 | 30 | $0 (2024) |
| Lilly USA, LLC | $286.63 | 12 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $258.37 | 15 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $246.28 | 12 | $0 (2021) |
| Genentech USA, Inc. | $209.36 | 14 | $0 (2020) |
| PFIZER INC. | $133.37 | 9 | $0 (2022) |
| Astellas Pharma US Inc | $113.10 | 7 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $90.26 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $78.31 | 4 | E.R. Squibb & Sons, L.L.C. ($78.31) |
| 2023 | $16.99 | 1 | E.R. Squibb & Sons, L.L.C. ($16.99) |
| 2022 | $248.18 | 9 | E.R. Squibb & Sons, L.L.C. ($114.93) |
| 2021 | $353.32 | 15 | E.R. Squibb & Sons, L.L.C. ($127.41) |
| 2020 | $377.65 | 17 | E.R. Squibb & Sons, L.L.C. ($149.11) |
| 2019 | $791.42 | 50 | Genentech USA, Inc. ($108.70) |
| 2018 | $6,573 | 58 | Merck Sharp & Dohme Corporation ($4,043) |
| 2017 | $674.74 | 36 | E.R. Squibb & Sons, L.L.C. ($226.34) |
All Payment Transactions
190 individual payment records from CMS Open Payments — Page 2 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/24/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $0.88 | General |
| Category: Oncology | ||||||
| 05/11/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $119.94 | General |
| Category: Oncology | ||||||
| 04/01/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $86.68 | General |
| Category: Oncology | ||||||
| 01/12/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2020 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: Oncology | ||||||
| 12/08/2020 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $12.24 | General |
| 12/03/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.50 | General |
| Category: Oncology | ||||||
| 11/24/2020 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2020 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: Oncology | ||||||
| 10/21/2020 | Puma Biotechnology, Inc. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2020 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $16.28 | General |
| 09/21/2020 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $11.55 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $7.95 | General |
| Category: Oncology | ||||||
| 03/04/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $11.89 | General |
| Category: ONCOLOGY | ||||||
| 02/27/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $121.41 | General |
| Category: Oncology | ||||||
| 02/26/2020 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: Oncology | ||||||
| 02/20/2020 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: BioOncology | ||||||
| 02/12/2020 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug), TASIGNA | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: ONCOLOGY | ||||||
| 02/06/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $6.25 | General |
| Category: Oncology | ||||||
| 02/05/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: Oncology | ||||||
| 01/23/2020 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $26.63 | General |
| Category: Oncology/Endocrinology | ||||||
| 12/13/2019 | PFIZER INC. | IBRANCE (Drug), TALZENNA | Food and Beverage | In-kind items and services | $12.89 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2019 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: Oncology | ||||||
| 11/21/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.02 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 390 | 978 | $193,792 | $98,295 |
| 2022 | 4 | 444 | 1,078 | $210,717 | $107,363 |
| 2021 | 4 | 497 | 1,107 | $211,077 | $113,899 |
| 2020 | 5 | 601 | 1,290 | $409,369 | $80,472 |
Total Patients
1,932
Total Services
4,453
Medicare Billing
$400,030
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 165 | 714 | $147,084 | $75,163 | 51.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 102 | 102 | $21,836 | $13,066 | 59.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 97 | 134 | $21,708 | $8,798 | 40.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 26 | 28 | $3,164 | $1,268 | 40.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 170 | 726 | $150,174 | $76,984 | 51.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 135 | 209 | $34,020 | $14,400 | 42.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 108 | 108 | $22,454 | $14,353 | 63.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 31 | 35 | $4,069 | $1,626 | 40.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 167 | 600 | $124,424 | $67,873 | 54.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 174 | 342 | $55,890 | $26,160 | 46.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 111 | 111 | $23,072 | $15,795 | 68.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 13 | 15 | $3,296 | $2,092 | 63.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 32 | 39 | $4,395 | $1,979 | 45.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 268 | 825 | $267,318 | $46,931 | 17.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 130 | 226 | $79,058 | $18,715 | 23.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 57 | 57 | $17,286 | $7,176 | 41.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 127 | 163 | $37,430 | $5,740 | 15.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 19 | 19 | $8,277 | $1,910 | 23.1% |
About Dr. Theodore Pollock, DO
Dr. Theodore Pollock, DO is a Hematology & Oncology healthcare provider based in Grove City, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609817246.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Theodore Pollock, DO has received a total of $9,113 in payments from pharmaceutical and medical device companies, with $78.31 received in 2024. These payments were reported across 190 transactions from 32 companies. The most common payment nature is "Travel and Lodging" ($5,003).
As a Medicare-enrolled provider, Pollock has provided services to 1,932 Medicare beneficiaries, totaling 4,453 services with total Medicare billing of $400,030. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Internal Medicine
- Location Grove City, OH
- Active Since 06/08/2006
- Last Updated 12/03/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1609817246
Products in Payments
- KEYTRUDA (Biological) $4,168
- OPDIVO (Biological) $963.37
- CYRAMZA (Drug) $239.69
- TECENTRIQ (Biological) $139.55
- TAGRISSO (Drug) $99.47
- IBRANCE (Drug) $82.27
- Stivarga (Drug) $76.70
- MEKINIST (Drug) $73.12
- XTANDI (Drug) $66.33
- Revlimid (Drug) $50.53
- FOUNDATIONONE (Device) $50.11
- Bavencio (Biological) $49.17
- LYNPARZA (Drug) $47.68
- ALIMTA (Drug) $46.94
- TASIGNA (Drug) $44.72
- INJECTAFER (Drug) $44.70
- BENDEKA (Drug) $42.32
- AFINITOR (Drug) $42.26
- Ixempra (Drug) $40.91
- SOMATULINE DEPOT (Drug) $38.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.